Investigating treatment options for adolescent depression
Official title: Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD): a Pragmatic Clinical Trial
Run by First Affiliated Hospital of Chongqing Medical University · NCT05814640 · Data updated 2026-11-12
This study is testing different antidepressant options for teenagers with depression who haven't found relief from their first treatments to see which works best.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 13 Years to 18 Years |
| Sex | All |
| Enrollment | 520 (estimated) |
| Sponsor | First Affiliated Hospital of Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Province) |
| Status | Recruiting |
| Started | February 20, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | July 1, 2027 |
| Registry record updated | January 27, 2026 |
| Trial ID | NCT05814640 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adolescents aged 13 to 18 diagnosed with Major Depressive Disorder who have not adequately responded to initial antidepressant treatment.
✕Probably not a fit
Patients with a history of bipolar disorder, schizophrenia, or severe mental disorders requiring inpatient treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to evaluate the effectiveness of common antidepressants in treating adolescents with Major Depressive Disorder (MDD) who have not responded to initial treatments. It employs a Sequential Multiple Assignment Randomized Trial (SMART) design over 16 weeks, divided into two phases. In phase 1, participants will choose between fluoxetine or fluoxetine combined with cognitive behavioral therapy (CBT). Those who do not respond will be randomized in phase 2 to receive alternative medications or combinations to assess treatment remission and response rates.
Why it matters
Potential benefit: If successful, this study could provide effective treatment options for adolescents suffering from depression who have not responded to first-line therapies.
How similar studies have gone: Other studies have shown promise in using sequential treatment approaches for depression, suggesting potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 13 - 18 2. As assessed by K-SADS-PL, it meets the DSM-V criteria for MDD with non-psychotic symptoms 3. Score≥40 on the CDRS-R 4. Participants with suicidal ideation are eligible, as long as clinicians consider outpatient treatment to be safe 5. Sufficient audio-visual level to complete this study 6. Written informed consent was obtained from patients and at least one of their parents Exclusion Criteria: 1. History of bipolar disorder, schizophrenia, autism, eating disorders, primary obsessive compulsive disorder, pervasive developmental disorder, or psychosis not otherwise specified 2. History of serious physical illnesses 3. Substance abuse or dependence 4. Current depressive episode with clear suicidal plans or suicidal behavior 5. Requires inpatient treatment for psychiatric disorders 6. Severe mental disorders requiring 7. 2 or more failed trials of antidepressant drugs: each trial for at least 8 weeks, with the last 4 weeks at full dose (e.g. fluoxetine 40mg/d, citalopram 40mg/d, escitalopram 20mg/d, sertraline 150mg/d ) 8. History of clear-cut intolerability of, or lack of effect with, an adequate trial of at least one protocol treatment option 9. Taking any medicine that contraindicates in combination with or interferes with the efficacy of the treatment 10. Taking or administering antidepressants within 5 half-lives 11. Received modified electroconvulsive therapy within 12 months 12. If female, is pregnant
Where it's running
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Province, China Recruiting
Study contacts
- Study coordinator: Xinyu Zhou
- Email: zhouxinyu@cqmu.edu.cn
- Phone: 15823996993
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone-supported single-session psychotherapy for postpartum depression
A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.
-
Mindful Smartphone Use: A Mindfulness-Based Program for Teens with Sleep and Mood Challenges
This study tests Mindwire, a mindfulness-based program, to see if it helps teens with problematic phone use who also have depression or anxiety.
-
Tele-based wellbeing centres for women's mental health in Bangladesh
A randomized trial tests whether tele-counselling for depression and anxiety in Bangladeshi women is as effective as in-person counselling.
-
Remote monitoring for adults with depression using ThIA Suivi
This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.
-
HBOT to see if it helps cognition and well‑being in first responders with prior brain injury
This study tests whether 40 hyperbaric oxygen therapy sessions can improve thinking skills and post-concussion symptoms in current or former first responders with a history of brain injury.
-
Focused ultrasound for mood and anxiety disorders
This study tests whether repeated low-intensity focused ultrasound using the ATTN201 device can help people with subsyndromal to moderate depression, anxiety, or OCD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.